---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-004966"
form_type: "8-K"
ticker: "EWTX"
cik: "0001710072"
company_name: "Edgewise Therapeutics, Inc."
filed_at: "2024-01-19T23:59:59+00:00"
generated_at: "2026-06-06T21:21:42.941423+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Edgewise reports $318.4M cash, outlines 2024 milestones, terminates ATM program

## Summary
- Preliminary cash, equivalents and marketable securities of $318.4M as of Dec 31, 2023; shares outstanding 70.5M.
- EDG-5506: 24-month ARCH data (Becker MD) in H1 2024; 1-year CANYON data in Q4 2024.
- EDG-5506: Phase 2 DUNE exercise data (Becker, LGMD, McArdle) in H1 2024; 3-month LYNX data (Duchenne) in H1 2024.
- EDG-7500 Phase 1 data in healthy volunteers and oHCM patients expected Q3 2024.
- Terminated ATM equity program with BofA Securities; no further sales under existing prospectus.

## SEC filing metadata
- accession: 0001104659-24-004966
- form_type: 8-K
- ticker: EWTX
- cik: 0001710072
- company_name: Edgewise Therapeutics, Inc.
- filed_at: 2024-01-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1710072/000110465924004966/0001104659-24-004966-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1710072/000110465924004966/tm243583d3_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-004966
- JSON: https://secwatch.observer/filing/0001104659-24-004966.json
- Plain text: https://secwatch.observer/filing/0001104659-24-004966.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.